Alpha Cognition Inc. - Common Stock (NQ:ACOG)

9.190 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alpha Cognition Inc. - Common Stock

< Previous 1 2 3 Next >

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

October 13, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

October 06, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

October 01, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition (NASDAQ:ACOG) Q1 Revenue Meets Estimates as Commercial Momentum Builds ↗

May 14, 2026

Via Chartmill

Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q4 Revenue Miss Amid Strong Alzheimer's Drug Launch ↗

March 26, 2026

Via Chartmill

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 01, 2026

From Alpha Cognition Inc.

Via Business Wire

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

August 17, 2026

Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on...

Via Newsfile

Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%.

Via The Motley Fool

Topics Earnings

Alpha Cognition Q2 Earnings Call Highlights ↗

August 13, 2026

Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the...

Via MarketBeat

Topics Earnings

Alpha Cognition Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Alpha Cognition (NASDAQ:ACOG) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by...

Via Benzinga

Topics Earnings

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

August 13, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

August 03, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

July 29, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

July 10, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

June 23, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

June 16, 2026

From Alpha Cognition, Inc.

Via Business Wire

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease

June 09, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Q1 Earnings Call Highlights ↗

May 14, 2026

Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across...

Via MarketBeat

Topics Earnings

Alpha Cognition (ACOG) Q1 2026 Earnings Transcript ↗

May 14, 2026

Alpha Cognition (ACOG) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

May 14, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

April 28, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

April 27, 2026

From Alpha Cognition, Inc.

Via Business Wire

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

April 20, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 15, 2026

From Alpha Cognition Inc.

Via Business Wire

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

April 01, 2026

From Alpha Cognition Inc.

Via Business Wire

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

April 01, 2026

Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on...

Via Newsfile

Alpha Cognition (ACOG) Q4 2025 Earnings Transcript ↗

April 01, 2026

Alpha Cognition (ACOG) Q4 2025 Earnings Transcript

Via The Motley Fool

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

March 26, 2026

From Alpha Cognition Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.